Cancer Chemoprevention: a Rapidly Evolving Field

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Jun 6

PMID 23736035

Citations 122

Authors

W P Steward

K Brown

Affiliations

Soon will be listed here.

Abstract

Cancer chemoprevention involves the chronic administration of a synthetic, natural or biological agent to reduce or delay the occurrence of malignancy. The potential value of this approach has been demonstrated with trials in breast, prostate and colon cancer. The paradigm for developing new chemopreventive agents has changed markedly in the last decade and now involves extensive preclinical mechanistic evaluation of agents before clinical trials are instituted and a focus on defining biomarkers of activity that can be used as early predictors of efficacy. This review will summarise the current status of the field of chemoprevention and highlight potential new developments.

Citing Articles

Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.

Naponelli V, Piscazzi A, Mangieri D Int J Mol Sci. 2025; 26(3).

PMID: 39940882 PMC: 11818640. DOI: 10.3390/ijms26031114.

Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Manna E, Serrano D, Cazzaniga L, Mannucci S, Zanzottera C, Fava F Genes (Basel). 2025; 16(1).

PMID: 39858629 PMC: 11764557. DOI: 10.3390/genes16010082.

Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.

Hashim G, Shahgolzari M, Hefferon K, Yavari A, Venkataraman S Bioengineering (Basel). 2025; 12(1).

PMID: 39851281 PMC: 11759177. DOI: 10.3390/bioengineering12010007.

Evaluation of the Cancer-Preventive Effect of Resveratrol-Loaded Nanoparticles on the Formation and Growth of In Vitro Lung Tumor Spheroids.

Torrico Guzman E, Gravely M, Meenach S Pharmaceutics. 2025; 16(12).

PMID: 39771566 PMC: 11677875. DOI: 10.3390/pharmaceutics16121588.

Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment.

Hegde M, P R A, Mumbrekar K Heliyon. 2024; 10(23):e40809.

PMID: 39691196 PMC: 11650287. DOI: 10.1016/j.heliyon.2024.e40809.

References

Wu X, Lippman S . An intermittent approach for cancer chemoprevention. Nat Rev Cancer. 2011; 11(12):879-85. DOI: 10.1038/nrc3167. View

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

Yu S, Kong A . Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets. 2007; 7(5):416-24. DOI: 10.2174/156800907781386669. View

Rothwell P, Price J, Fowkes F, Zanchetti A, Roncaglioni M, Tognoni G . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826):1602-12. DOI: 10.1016/S0140-6736(11)61720-0. View

Algra A, Rothwell P . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13(5):518-27. DOI: 10.1016/S1470-2045(12)70112-2. View

Flossmann E, Rothwell P . Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573):1603-13. DOI: 10.1016/S0140-6736(07)60747-8. View

Albanes D, Heinonen O, Taylor P, Virtamo J, Edwards B, Rautalahti M . Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996; 88(21):1560-70. DOI: 10.1093/jnci/88.21.1560. View

Rothwell P, Wilson M, Elwin C, Norrving B, Algra A, Warlow C . Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376(9754):1741-50. DOI: 10.1016/S0140-6736(10)61543-7. View

Lippman S, Klein E, Goodman P, Lucia M, Thompson I, Ford L . Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2008; 301(1):39-51. PMC: 3682779. DOI: 10.1001/jama.2008.864. View

10.

Sporn M . Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976; 36(7 PT 2):2699-702. View

11.

Kummar S, Doroshow J . Phase 0 trials: expediting the development of chemoprevention agents. Cancer Prev Res (Phila). 2011; 4(3):288-92. PMC: 3077921. DOI: 10.1158/1940-6207.CAPR-11-0013. View

12.

Burn J, Gerdes A, Macrae F, Mecklin J, Moeslein G, Olschwang S . Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378(9809):2081-7. PMC: 3243929. DOI: 10.1016/S0140-6736(11)61049-0. View

13.

Cuzick J, Forbes J, Sestak I, Cawthorn S, Hamed H, Holli K . Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007; 99(4):272-82. DOI: 10.1093/jnci/djk049. View

14.

Kelloff G, Johnson J, Crowell J, Boone C, DeGeorge J, Steele V . Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev. 1995; 4(1):1-10. View

15.

West N, Clark S, Phillips R, Hutchinson J, Leicester R, Belluzzi A . Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010; 59(7):918-25. DOI: 10.1136/gut.2009.200642. View

16.

Harris R, Chlebowski R, Jackson R, Frid D, Ascenseo J, Anderson G . Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003; 63(18):6096-101. View

17.

OShaughnessy J, Kelloff G, Gordon G, Dannenberg A, Hong W, Fabian C . Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002; 8(2):314-46. View

18.

Duffield-Lillico A, Reid M, Turnbull B, Combs Jr G, Slate E, Fischbach L . Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev. 2002; 11(7):630-9. View

19.

Gerhauser C, Bartsch H, Crowell J, De Flora S, DIncalci M, Dittrich C . Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. Eur J Cancer. 2006; 42(10):1338-43. DOI: 10.1016/j.ejca.2006.02.007. View

20.

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View